Of particular interest, recent data from the Atherosclerosis Risk in Communities (ARIC) study and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study have shown that glycated hemoglobin is a better predictor for all-cause and cardiovascular mortality than fasting glucose (9, 10) .
The objective of the present work in 2,002 LURIC participants was to analyze whether subjects with newly diagnosed type 2 diabetes as per the ADA 2010 definition who would not have received the diagnosis as per the ADA 2009 definition are at increased risk of death from any cause and from cardiovascular diseases (10, 11) .
RESEARCH DESIGN AND METHODSdLURIC is a cross-sectional and prospective clinical trial that was designed to investigate cardiovascular risk factors. A total of 3,316 white subjects were recruited between July 1997 and January 2000 at the Ludwigshafen Heart Center in southwestern Germany (10, 11) . All participants underwent coronary angiography. The precise inclusion/exclusion criteria have been previously described (10, 11) . For the present analyses, subjects with known diabetes or incomplete determination of the glucometabolic phenotype (missing 75-g oral glucose tolerance test despite fasting glucose ,126 mg/dL) were additionally ruled out. Information on the cause of death was missing for 11 decedents. These people were excluded when data on cardiovascular mortality were analyzed. The study was approved by the ethics committee at the Ärztekammer Rheinland-Pfalz and was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all participants (10) . Diabetes was diagnosed according to the 2009 and 2010 criteria of the ADA (1,2). The follow-up for all-cause and cardiovascular mortality had a mean duration 6 SD of 7.7 6 2.0 years.
Laboratory analyses
The laboratory methods have been reported previously (10, 11) . Glucose was measured enzymatically on a Hitachi 717 analyzer (Roche, Mannheim, Germany). Glycated hemoglobin was measured with an immunoassay (hemoglobin A 1c UNIMATE 5; Hoffmann-LaRoche, Grenzach-Whylen, Germany).
Statistical analysis
The baseline clinical and biochemical characteristics are presented for three Categorical data are expressed as numbers and percentages. In the case of continuous variables, we report means with SDs or medians with interquartile ranges. P values for differences in baseline characteristics among the three groups were calculated with the x 2 test for categorical data and with ANOVA for continuous variables. Triglycerides and insulin were transformed logarithmically before being used in parametric statistical procedures. The Cox proportional hazards model was used to test the relationships of the three groups with all-cause and cardiovascular mortality. Two predefined models of adjustment were used (model 1: univariate; model 2: adjusted for sex, age, BMI, hypertension, smoking, glomerular filtration rate, triglycerides, LDL cholesterol, and HDL cholesterol). The results are presented as hazard ratios with 95% CIs. All statistical tests were two-sided and P , 0.05 was considered significant. The SPSS 15.0 statistical package (SPSS Inc., Chicago, IL) was used.
RESULTSdThe clinical and biochemical characteristics of the study participants and data on mortality are shown in Table 1 There is broad evidence that type 2 diabetes will increase the risk of cardiovascular death (12) (13) (14) . Thus far, only subjects with elevated fasting or postchallenge glucose were diagnosed with diabetes (1). However, fasting and postchallenge glucose have high intraindividual variability (15) . Hence, the sensitivity of these tests to select subjects with disturbance of glucose metabolism is not optimal.
Our data support that the use of glycated hemoglobin at a cut point of $6.5% as an additional criterion for the diagnosis of diabetes may improve cardiovascular risk stratification in subjects referred for coronary angiography. Future studies should attempt to answer the question whether measurement of glycated hemoglobin will obviate the need for oral glucose tolerance testing.
